Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$9.99 - $18.71 $1.06 Million - $1.99 Million
-106,132 Reduced 75.15%
35,087 $651,000
Q2 2023

Aug 10, 2023

BUY
$9.17 - $19.29 $583,771 - $1.23 Million
63,661 Added 82.08%
141,219 $1.56 Million
Q1 2023

May 11, 2023

SELL
$12.53 - $21.71 $5.68 Million - $9.83 Million
-453,009 Reduced 85.38%
77,558 $1.04 Million
Q4 2022

Feb 13, 2023

BUY
$11.61 - $16.11 $5.19 Million - $7.2 Million
446,628 Added 532.09%
530,567 $6.56 Million
Q3 2022

Nov 10, 2022

BUY
$12.21 - $19.7 $1.02 Million - $1.65 Million
83,939 New
83,939 $1.17 Million
Q2 2022

Aug 19, 2022

SELL
$11.23 - $19.59 $390,186 - $680,654
-34,745 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$13.37 - $17.79 $1.64 Million - $2.19 Million
-122,918 Reduced 77.96%
34,745 $565,000
Q4 2021

Feb 11, 2022

BUY
$14.28 - $19.53 $1.84 Million - $2.52 Million
129,030 Added 450.63%
157,663 $2.57 Million
Q3 2021

Nov 15, 2021

BUY
$12.99 - $20.47 $233,794 - $368,419
17,998 Added 169.23%
28,633 $425,000
Q2 2021

Aug 16, 2021

SELL
$15.46 - $24.5 $114,713 - $181,790
-7,420 Reduced 41.1%
10,635 $212,000
Q1 2021

May 17, 2021

SELL
$19.33 - $37.75 $16,894 - $32,993
-874 Reduced 4.62%
18,055 $417,000
Q4 2020

Feb 16, 2021

BUY
$24.48 - $42.47 $463,381 - $803,914
18,929 New
18,929 $468,000
Q3 2020

Nov 16, 2020

SELL
$39.09 - $53.44 $1.6 Million - $2.19 Million
-40,941 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$46.7 - $92.04 $1.91 Million - $3.77 Million
40,941 New
40,941 $1.96 Million
Q3 2019

Nov 14, 2019

SELL
$58.69 - $80.46 $199,546 - $273,564
-3,400 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$77.77 - $120.68 $124,743 - $193,570
1,604 Added 89.31%
3,400 $271,000
Q1 2019

May 15, 2019

BUY
$91.83 - $120.68 $164,926 - $216,741
1,796 New
1,796 $201,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.